Skip to content
Findings

Finding search

Search what regulators worldwide cited at pharmaceutical sites, in the original wording.

5,289 documents · 24,590 findings · as of 2026-11-14

Loading…

24 most recent documents — search or filter for live results

2026-11-13FDA 483Dr. Reddy's Laboratories Ltd.Aseptic processing and sterility assurance · Contamination controlAseptic processing environmental monitoring procedures are inadequate in them filling line. 2026-11-13FDA 483Qingdao Kangyuan Pharmaceutical Co., LTDOther quality system · Equipment and facility · Laboratory and QC controlsSOP 09-301 requires analytical balances to be placed on a vibration proof surface. 2026-11-13FDA 483Qingdao Kangyuan Pharmaceutical Co., LTDEquipment and facility · Other quality system · Contamination control · Material and supplier controlThe written procedure, Gauge and Calibration Management, SOP 03-103, version 02, effective date 7/20/15, did not include adequate instructions regarding where a… 2026-11-13FDA 483Qingdao Kangyuan Pharmaceutical Co., LTDLaboratory and QC controls · Other quality system · Documentation and recordsLaboratory controls do not include scientifically sound and appropriate specifications, sampling plans and test procedures designed to assure that raw materials… 2026-11-13FDA 483Avaria Health & Beauty CorpOther quality system · Quality unit oversight · Laboratory and QC controls · Equipment and facility · Material and supplier controlThe number of containers to be sampled is not based upon appropriate criteria. 2026-11-13FDA 483Guangxi Yulin Pharmaceutical Group Co. Ltd.Equipment and facility · Stability and storage · Laboratory and QC controls · Process validation · Labeling and packagingEquipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality, or purity of… 2026-11-13FDA 483Phoenix Innovative Healthcare Manufactures Private LimitedDeviation, CAPA, and investigation · Equipment and facility · Other quality systemThere is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whethe… 2026-11-13FDA 483Packagina On Demand, Inc.Other quality system · Laboratory and QC controls · Equipment and facility · Material and supplier controlIn-process specifications are not derived from previous acceptable process average and process variability estimates where possible. 2026-11-13FDA 483Huangshi Hygenic Material Medicine Co.Stability and storage · Laboratory and QC controls · Equipment and facilityAn adequate number of batches of each drug product are not tested nor are records of such data maintained to determine an appropriate expiration date. 2026-11-13FDA 483Tripak Pharmaceuticals Pty Ltd.Material and supplier control · Stability and storage · Quality unit oversight · Process validation · Laboratory and QC controlsSpecific identification tests are not conducted on components that have been accepted based on the supplier's report of analysis. 2026-11-13FDA 483Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd.Quality unit oversight · Equipment and facility · Material and supplier controlThe responsibilities and procedures applicable to the quality control unit are not fully followed. 2026-11-13FDA 483Linhai Tianyu Pharmaceutical Co., Ltd.Equipment and facility · Laboratory and QC controls · Computer system validationFacilities and equipment used in the manufacturing of drug substances are not adequately maintained. 2026-11-13FDA 483Glenmark Pharmaceuticals Inc USALaboratory and QC controls · Quality unit oversight · Training and personnel · Process validation · Equipment and facility · Stability and storage · Aseptic processing and sterility assurance · Deviation, CAPA, and investigationThe accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented. 2026-11-13FDA 483Lyophilization Services of New England, Inc. dba PCI Pharma ServicesAseptic processing and sterility assurance · Equipment and facility · Process validationProcedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed. 2026-11-13FDA 483BSP Pharmaceuticals S.p.A.Other quality system · Equipment and facilityProcedure QC-001 for Management ofOut of Specification and Out-of-Alert limits is inadequate. 2026-11-13FDA 483BSP Pharmaceuticals S.p.A.Equipment and facility · Other quality system · Process validationEquipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use. 2026-11-13FDA 483Strive Pharmacy LLCContamination control · Aseptic processing and sterility assurance · Training and personnelMicrobial contamination was present in the ISO 5 area and areas adjacent to production areas. 2026-11-13FDA 483Hybrid Pharma LLCAseptic processing and sterility assurance · Training and personnel · Laboratory and QC controls · Equipment and facility · Process validation · Regulatory reporting and change controlDrug product containers and closures were not sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use. 2026-11-12FDA 483Raptim Research Private LimitedOther quality system · Documentation and records · Computer system validation · Laboratory and QC controlsThe in vitro sample disposal record dated 14/May/2025 documents that the samples were retrieved for disposal from freezer number INS/ANA/269. 2026-11-12FDA 483Neva Analytics, LLCOther quality system · Deviation, CAPA, and investigation · Laboratory and QC controls · Computer system validation · Complaint and recall handling · Quality unit oversightRefrigerator _ ()(4) stored USP References used to execute HPLC assays. 2026-11-12FDA 483KDC/ONE Socal Laboratories, LLCEquipment and facility · Quality unit oversight · Stability and storage · Laboratory and QC controlsEquipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, streng… 2026-11-12FDA 483Similasan AGLaboratory and QC controls · Process validation · Equipment and facilityDeterminations of conformance to appropriate written specifications for acceptance are deficient in that they are not made for each lot within each shipment of… 2026-11-12FDA 483Orean Personal Care LtdProcess validation · Computer system validation · Equipment and facility · Material and supplier control · Other quality system · Laboratory and QC controls · Deviation, CAPA, and investigationThere are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity t… 2026-11-12FDA 483Genzyme Ireland LimitedAseptic processing and sterility assurance · Other quality system · Equipment and facilityProcedures, process and testing designed to prevent microbial contamination of the drug product purporting to be sterile are not established.
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.

The Korean is a generative-AI translation shown with the original for each item. Dates are publication dates (inspection dates for Health Canada); rely on the original. About sources and AI use